Innovation Drives Divergence: US FDA Drugs and Biologics Centers Follow Own Trajectories

The long-building wave of cell and gene therapies has transformed the profile of novel approvals at the US Food and Drug Administration’s Center for Biologics Evaluation and Research, placing it on a growth trajectory increasingly divergent from the larger Center for Drug Evaluation and Research.